A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid Tumor
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label and multicenter study of SY-4798, a highly specific and potent
inhibitor of FGFR4, in patients with advanced solid tumor. This study has two phases:
dose-escalation phase and dose-expansion phase.